MedTrace Logo

Bacillus Clausii in Liver Transplantation

NCT05047406 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-07-24

No results posted yet for this study

Summary

A prospective, randomized, controlled study of the safety and efficacy of using Bacillus clausii probiotic oral preparation to decrease the incidence of infection during the first 30 days after living donor liver transplantation surgery.

Conditions

  • Transplantation Infection
  • Liver Grafting
  • Hepatic Transplantation

Interventions

DIETARY_SUPPLEMENT

Bacillus clausii Probiotic liquid

mini bottles for oral administration containing 2 million spores of Bacillus clausii

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Rana Sayed, PhD · Faculty of Pharmacy, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-07
Primary Completion
2023-05-30
Completion
2023-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047406 on ClinicalTrials.gov